ABOS vs ALNY · $73.3M cap vs P/E 76, rev $1.29B
Acumen Pharmaceuticals Inc (ABOS) versus Alnylam Pharmaceuticals Inc (ALNY) — a side-by-side from cached financials, not a winner call.
Acumen Pharmaceuticals Inc (ABOS) is a biotechnology company listed on US.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
ABOS does not have a complete income-statement cache yet.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
ABOS currently screens at market cap $73.3M. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Not investment advice. Open the ABOS and ALNY stock pages for the full models.
Not investment advice.